Sarcoma  >>  letetresgene autoleucel (GSK3377794)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
letetresgene autoleucel (GSK3377794) / Adaptimmune
ADP 04511, NCT01343043 / 2015-005594-21: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Completed
1
50
US
NY-ESO-1(c259)T Cells, Fludarabine, Cyclophosphamide
GlaxoSmithKline
Neoplasms
06/19
06/19

Download Options